Dive Medicine

Erythromelalgia and Hyperbaric Oxygen

7 min read · 24 March 2026
Hero illustration for the article “Erythromelalgia and Hyperbaric Oxygen”

Updated: October 20, 2026

A 1999 meeting abstract by Potkin, Weinberger, Comer and Dale, titled Successful Treatment of Erythromelalgia with Hyperbaric Oxygen, raised a focused question: could hyperbaric oxygen help a patient with erythromelalgia? The bibliographic record identifies it as an abstract in Undersea & Hyperbaric Medicine, not a full clinical trial report. That distinction matters: the title signals a reported treatment outcome, but the available record supplied here does not establish the patient’s details, treatment protocol, durability of benefit or safety findings.

What is erythromelalgia?

Erythromelalgia is a clinical syndrome of episodic burning pain, redness and increased skin temperature, most often in the feet or hands. Heat, exercise, standing or tight footwear can trigger attacks; some patients find that elevation or gentle cooling helps. Symptoms and triggers vary, so a description of one person’s episodes cannot establish the cause in another.

Clinicians distinguish primary erythromelalgia from secondary forms associated with another disorder. Primary disease can be linked to variants in SCN9A, the gene encoding the Nav1.7 sodium channel, while secondary erythromelalgia may accompany myeloproliferative neoplasms such as essential thrombocythaemia or polycythaemia vera. A complete assessment therefore considers the history, examination, medication list and appropriate blood tests; aspirin responsiveness can be relevant in some platelet-associated cases, but is not a diagnostic test for everyone.

The redness and heat do not mean that the tissue simply lacks oxygen. Erythromelalgia involves abnormal interactions among small-vessel blood flow, temperature regulation and sensory nerves. Prolonged ice-water immersion is particularly risky: it can injure skin and cause maceration or ulcers, so cooling should be cautious rather than extreme.

What does hyperbaric oxygen involve?

Hyperbaric oxygen therapy (HBOT) is delivered in a pressure chamber, where a patient breathes near-100% oxygen at pressure above the surrounding atmosphere. A common clinical range is about 2.0–2.5 atmospheres absolute (ATA), often for roughly 90 minutes of oxygen breathing, with the precise prescription depending on the indication and facility. These are representative treatment conditions, not a protocol that can be inferred for the 1999 case.

At elevated pressure, more oxygen dissolves in plasma; oxygen transport is not limited to the amount bound to haemoglobin. The effect depends on pressure, exposure time, circulation and the patient’s condition. HBOT is not simply high-flow oxygen at normal pressure, and it is not an established routine treatment for erythromelalgia. The 1999 title is a report of successful treatment, not proof from controlled comparison that HBOT is effective for the syndrome generally.

Chamber care also has risks. Middle-ear or sinus barotrauma, temporary visual changes and oxygen-toxicity seizures are recognized complications; pulmonary barotrauma is uncommon but serious. Claustrophobia and the ability to equalize ear pressure also matter. An untreated pneumothorax is a major contraindication, and clinicians must assess other risks before treatment.

Why is this subject relevant to diving medicine?

Diving and HBOT share pressure and gas-physiology principles, but their purposes differ. A diver changes ambient pressure while breathing compressed gas underwater; a patient in HBOT receives a prescribed chamber exposure for a medical indication. For comparison, seawater pressure rises by about 1 ATA per 10 metres of depth, whereas a chamber treatment is specified by its absolute pressure, oxygen exposure and clinical indication.

Erythromelalgia is relevant to dive medicine because painful, heat-sensitive extremities may affect equipment tolerance, mobility and the ability to respond to an emergency. Symptoms alone do not decide fitness to dive. A diving-medicine physician should assess attack frequency, cause, medication effects, complications and whether cold exposure or exertion provokes symptoms. A chamber treatment for erythromelalgia should likewise be considered by a qualified hyperbaric team—not treated as an extension of routine dive care.

What concepts help frame the research question?

The abstract can be read as an early clinical observation at the intersection of oxygen transport and peripheral vascular symptoms. Its central biological question is not merely whether oxygen can be increased, but whether changing oxygen availability under pressure can improve a syndrome whose mechanisms include neural and vascular regulation.

  • Oxygen delivery: tissue supply depends on blood flow as well as oxygen content; increasing dissolved oxygen does not automatically correct abnormal vascular control.
  • Vascular and neural mechanisms: Nav1.7-related pain signalling and small-vessel changes offer different potential targets, so a response to treatment would not by itself identify the mechanism.
  • Pressure and exposure: an interpretable HBOT report needs chamber pressure in ATA, oxygen-breathing duration, number of sessions and outcome timing.
  • Evidence quality: a meeting abstract is not equivalent to a randomized controlled trial, and a single reported success cannot determine average benefit, harms or who might respond.

In current practice, HBOT is generally reserved for accepted indications supported by clinical evidence and specialist guidance. Erythromelalgia is not among the standard indications listed by the Undersea and Hyperbaric Medical Society. The 1999 report is therefore best understood as a historical case-level signal that may prompt questions, not as a treatment recommendation. Evaluating the claim would require the full report and, ideally, independently replicated clinical evidence.

  • 1999 publication year recorded for the Potkin and colleagues meeting abstract
  • 2.0–2.5 ATA representative pressure range used in many clinical HBOT protocols; not confirmed for this case
  • About 10 m seawater per 1 ATA approximate pressure increase relevant to diving, not a treatment conversion
How the 1999 report differs from established clinical evidence
Question 1999 erythromelalgia report Evidence needed for a treatment recommendation
Publication type Meeting abstract Full methods and independently reviewable results
What can be concluded? The title reports a successful treatment Comparative evidence on benefit, harms and patient selection
Protocol details Not established by the bibliographic record Pressure in ATA, session duration, course length and follow-up

Frequently asked questions

What does the publication report?

Its 1999 title reports successful hyperbaric oxygen treatment for erythromelalgia. The repository record identifies a meeting abstract; it does not provide enough information to verify protocol details or generalize the result.

Is hyperbaric oxygen an established treatment for erythromelalgia?

No. A single meeting abstract is not sufficient evidence to establish routine efficacy, and erythromelalgia is not a standard UHMS-listed HBOT indication. Patients should discuss established diagnostic and management options with their treating clinician.

Does erythromelalgia automatically prevent diving?

No. Fitness depends on the cause and severity of symptoms, their triggers, treatment effects and the practical demands of the planned dive. Seek an individualized assessment from a physician trained in diving medicine.

Citation details

  • Title: Successful Treatment of Erythromelalgia with Hyperbaric Oxygen
  • Authors: Potkin, RT; Weinberger, A; Comer, M; Dale, HM
  • Year: 1999
  • Journal: Undersea & Hyperbaric Medicine
  • Record type: Meeting abstract
  • Repository record: Rubicon Research Repository, handle 123456789/803

This is an editorial summary of the bibliographic record, not a reproduction of the abstract or its data. The repository entry does not, by itself, supply the treatment methods or outcome measurements; consult the original publication for those details.

Related reading on Rubicon

  • The physiology behind oxygen toxicity in deep dives
  • Understanding oxygen-toxicity risks and prevention in diving
  • Oxygen partial pressure and dive safety
  • Oxygen-toxicity limits in diving
  • Hyperbaric oxygen therapy for Lyme disease
  • Research in diving and hyperbaric medicine
  • More on dive medicine
  • Browse the research library